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Evidence  implicating  murine  leukemia-like  virus  in  the  etiology  of  the 
hemolytic, renal, and neoplastic disorders of NZB mice has been presented else- 
where (1-5).  Further substantiation of the relation of virus infection to disease 
is now afforded in the study of antigens associated with routine leukemia virus 
(MuLV). These antigens include MuLV group-specific or nucleocapsid antigen 
common to the  several strains of murine leukemia and  sarcoma viruses and 
detectable by immunoprecipitation  (6); MuLV group antigens with  group and 
type  specificities  detectable  by  complement fixation  (7-9);  G  (Gross,  G+) 
antigen, type-specific cell-surface antigen associated with Gross leukemia virus 
(10,  11);  and  G  (Gross)  soluble  antigen,  a  recently discovered  type-specific 
soluble antigen (12-14). 
MuLV nucleocapsid antigen has already been identified in extracts of spleen, 
kidney, and milk of NZB mice by immunoprecipitation (15).  NZB mice have 
also been shown to be a  G+  mouse strain  by cytotoxic test (15).  In prelim- 
inary work, MuLV group antigens and host immunoglobulins have been demon- 
strated byimmunofluoreseence in the glomerular lesions of NZB mice with renal 
disease (5). 
Methods and Materials 
Mice.--The colony  of NZB mice  was derived from breeding stock provided by Dr. Marianne 
Bielschowsky in  1964 and has been maintained since then by brother-sister matings. The 
general methods of care and study of these mice have been described elsewhere (16), including 
monthly  antiglobulin  (Coombs) tests,  proteinuria  tests,  and  autopsy  and  histopathology 
procedures. C57BL/6, AKR, and C58 mice were obtained from our colonies. 
Leukemias and Other Neoplasms.--The lymphomas and sarcomas arose spontaneously in 
NZB mice and in some instances were carried as cell-passage  lines within this strain, as indi- 
cated elsewhere  (1, 4,17,18).  The sarcomas were osteogenic sarcomas (4, 19) and one example 
of soft tissue sarcoma. The G+ test cell for the determination of G antibody was the trans. 
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planted C57BL/6 leukemia Ec~G2  (10)  originally induced by Passage A  Gross virus  (22). 
EL4  cells were  the long-term transplanted  ascites leukemia  converted  from  a  chemically 
induced leukemia in C57BL mice (23). 
Vaccination  of NZB Mice.--A vaccine was prepared aseptically, by the method of Friend 
(20)  and used as described elsewhere (4,  5). Formaldehyde  was  added  to  cell-free filtrates 
of 10-20% extracts of aged NZB mouse spleens to obtain a  final concentration of 1: 500. The 
mixture was kept at 4°C  for  14-21  days,  with daffy shaking of contents, and then passed 
through 0.45 #  Milllpore filters. Two intraperitoneal injections of vaccine in 0.2  ml amounts 
were given to baby NZB mice, generally at 3 and 5 wk of age. 
MuLV Group Ant/gens.--The complement fixation (CF) method for detection of murine 
leukemia virus group antigens is described elsewhere (7,  8). The rat antiserums used in the 
CF test were obtained from inbred Fischer rats bearing isologous transplanted lymphomas or 
sarcomas induced respectively by murlne leukemia viruses or the Moloney strain of murine 
sarcoma  virus  (21).  These  serums  were carefully selected not only for antibody specificity 
with respect to MuLV group antigens but also for absence of nonspecific reactions with extracts 
of normal tissues (spleen, thymus, kidney) of various mouse strains and other control tissues. 
TABLE  I 
MuLV Group Antigens in Tissue Extracts  of Untreated NZB Mice at  Various  Ages 
NZB Mice  Tissue Extract 
Age  No.  Thymus  [  Spleen  ]  Kidney 
5 days 
21-24 days 
5 months 
9-18 months 
3/3 
4/5 
4/5 
2/5 
No. antigen-l>osltive/No, tested 
1/1 
5/5 
S/5 
5/5 
4/4 
5/5 
5/5 
5/5 
Total ..................  20  13/18  16/16  19/19 
10% extracts of tissues were screened at dilutions of 1:2 and 1:4. Positive 3 +  to 4+ reactions 
at a dilution of 1:2 or 1:4, in the absence of anticomplementary effects and in the absence of 
positive reactions in negative control extracts,  were  scored  as  positive  (Tables I  and  II). 
Concentrates of tissue extracts were prepared by a modification (47) of the Moloney procedure. 
MuLV Group IF Antigens.--The  indirect immunofluorescence (IF) method for the loca- 
tion  of  routine leukemia virus group IF antigens in frozen sections of NZB mouse tissues 
utilized precipitating antiserum prepared and kindly provided by Geering, Old,  and Boyse 
(6). The pooled antiserum with precipitating activity for Mu.LV group antigens was obtained 
from  (W/Fu  X  BN)FI rats bearing subcutaneous transplants of the  Gross virus induced 
leukemia W/Fu (C58NT)D. This antiserum  did not contain HI polyoma antibody (6) and 
was shown not to react in immunodiffusion tests with mouse serum in various dilutions or 
with mouse albumin, or-, fl-, and w-globulins over a wide range of concentrations. Fluorescein- 
labeled rabbit antibody against rat serum globulins (Microbiological Associates,  Bethesda, 
Md.)  was  carefully  absorbed with lyophillzed mouse  serum until no  longer reactive with 
mouse serum proteins although continuing to show  a  single line d  precipitation of  rat T- 
globulins in immunodiffnsion reactions with  rat  serum.  Negative control reactions in  the 
indirect immunofluorescence method  included the  use  of  normal  (nonimmune) W/Fu  rat 
serum and immune (W/Fu  X  BN)FI rat serum completely absorbed with,  and no longer 
reactive with, MuLV group antigens released from Gross virus by ether treatment of infective R.  C.  MELLORS~  T.  AOKI 3  AND  R.  J.  HUEBNER  1047 
W/Fu rat plasma; additional negative controls included frozen sections d  kidneys of normal 
Swiss mice. Direct staining reactions with fluorescent anti-rat globulin were negative. Fluores- 
ceindsbeled rabbit antibody against mouse immunoglobulins was used to locate mouse im- 
munoglobulins in sections of NZB mouse kidneys and spleens,  as described elsewhere (16). 
G (Gross) Typing Serum.--This serum was prepared by immunization of C57BL/6 female 
mice with the G-l- AKR 9  spontaneous leukemia K36. This serum did not contain HI poly- 
oma antibody. A complete description of the C~typing system was given elsewhere (10). 
Determination of G Ant~body.--The  sera were tested for G  antibody by the indirect im- 
munofluorescence test, as modified by Mdller for use with suspensions  of viable cells. Suspen- 
sions of viable ECG2 leukemia cells were prepared from the spleens of C57BL/6 mice bear- 
ing transplants  of  Ec~G2.  After two  or  three  washings  in  Earle's balanced  salt  solution 
(EBSS), 1-2 X  106 ceils were resnspended in 0.05 ml of undiluted serum and were incubated 
TABLE II 
MuLV Group Antigens  in Malignant  Lymphomas  and Sarcomas of NZB Mice 
Lymphoma or tumor  Lymphenm or tumor  Spleen 
Classification  No. of indepen-  dent lines  Extract  Concentrate  Extract 
No. ant~gen-posltlve/No, tested 
Lymphoma 
Primary 
Transplantable 
Sarcoma 
Transplantable 
2 
4 
2/2 
5/5  1/1 
5/6 
2/2 
3/3 
5  i/i  9/9 
Total .......................  11  8/8  7/7  14/14 
at room temperature for 20 rain. The cells were then washed twice in EBSS and resuspended 
in 0.05  ml of 1:80 diluted fluorescinated goat globulin anti-mouse globulin (Lot No.  12-65, 
Hyland Lab., Los Angeles, Calif.); this reagent gave a  strong single IgG line on immuno- 
electrophoresis with mouse serum. After incubation for 20 rain at room temperature, the cells 
were washed twice, and approximately 100 cells were examined for fluorescence.  Reactions 
were graded  according to the proportion of cells showing characteristic membrane fluores- 
cence:  =<200/0: negative; 21-50%:  weak  +;  51-100%:  strong  -{-. A  complete description 
of this method was given elsewhere (24). 
Demonstration of G Soluble Antigen Adsorbed on Viable Indicator Cdls.--Ascites leukemia 
EL4 cells served as the indicator cells; EIA does not carry G or FMR cellular antigens (10). 
After two or three washings in EBSS, 1-2 X  10  e EIA cells were suspended in 0.1 ml of the 
undiluted plasma, freshly drawn, to be tested for G soluble antigen and incubated for 30 rain 
at room temperature and 30 rain at CC. After two more washings in 2.0 ml EBSS, the cells 
were tested for adsorbed  G  soluble antigen by indirect immunofluorescence with G-typing 
serum as described above. The plasma of AKR or C58 mice served as positive controls. A 
detailed description of this method was given elsewhere (12). 
RESULTS 
MuLV  Group Anligens.--The complement-fixation (CF) test for the presence 
of murine  leukemia virus group antigens  was performed  on 53  tissue  extracts 
(Table I).  Spleen and kidneys of untreated  NZB mice were positive in all tests 1048  MU'RINE  LEUKEMIA-LIKE  VIRUS  AND  NZB  MICE 
at all ages examined (5 days to 18 months). Thymus was positive in each test 
at 5 days of age and in the majority of tests  performed  thereafter.  15 lym- 
phoma and sarcoma extracts and concentrates (Table H) gave positive results 
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FIG.  1.  Tests (% positive) for G soluble antigen (0) and G antibody (C)) in plasma and 
serum of NZB mice at various ages. 
in each instance, as did spleen extracts of lymphomatous and tumor-bearing 
NZB  mice.  The  malignant  lymphomas  included  two  primary  and  four 
transplantable lymphomas of NZB mice. Among the transplantable sarcomas 
were four independent cell-passage lines  of osteogenic sarcoma  and  one soft 
tissue sarcoma, all indigenous to the mouse strain NZB. 
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selected not only for antibody specificity with respect to MuLV group antigens 
but also for absence of nonspecific  reactions with extracts of normal mouse 
tissues and other control tissues and  with a  complete battery of the known 
conventional murine viral antigens. 
G Soluble Antigen.--107 untreated NZB mice at various ages were tested for 
G  soluble antigen in plasma  (Fig.  1). Positive reactions occurred in  10% of 
plasmas at 3 months. Thereafter, G soluble antigen production increased rapidly 
in line with age, with 50 % positive reactions at 5.3 months  (Table III)  and 
100% positive reactions at 7 to 9 months.  Beyond the 9th month,  G soluble 
antigen underwent elimination from plasma, with positive reactions reduced to 
TABLE III 
50O7o Response Time (T~o%)  for G Soluble  Antigen Production and Ebimination and G Antibody 
Production in  Untreated NZB  Mice 
Rcspom~e 
G soluble antigen production 
G soluble antigen elimination 
G natural antibody 
Ti0%*  -4-2 ~  ~  N ~ 
5.3  0.8  1.4  26 
13.3  1.2  2.9  42 
13.3  0.8  1.4  21 
* Estimated by logarithmic-probit graphic procedure and based upon N' determinations 
in the 6.7-93.3% range of response. Standard error (sw.) equals SD  -- A/N~  . 
"V  2 
50 % at 13.3 months (Table III) and to 0 % at 18 months. The results obtained 
on individual plasmas are shown in Fig. 2.  The reactions were graded by the 
proportion of cells showing membrane immunofluorescence  (see Methods and 
Materials) as negative (~_ 20 %), weak positive (21-50 %), and strong positive 
(51-100%), corresponding in turn to the time sequence of reactions in G soluble 
antigen production and to the reverse order in G soluble antigen elimiuation. 
The serums of 39 untreated NZB mice at 3, 7, 9, and 12 months of age were 
tested for antibody to cell membrane of EIA indicator cells (see Methods and 
Materials). All reactions were negative. 
G Natural Antibody.--51 untreated NZB mice at various ages were tested for 
G natural  antibody in  serum (Fig.  1).  Reactions were  negative  at  4  and 8 
months.  Positive reactions  occurred in 10 % of  serums at 10 months and in- 
creased  thereafter  in  line  with  age.  The 50 % positive response time (Table 
III) was 13.3 months. The results obtained on individual serums are shown in 
Fig. 3.  As discussed under Methods and Materials, reactions were graded by 
the proportion of cells  showing  membrane fluorescence,  as follows:  negative 
(<-20 %), weak positive (21-50 %), and strong positive (51-100 %). 
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a  reciprocal relation  to  each  other  (Fig.  1)  with  crossover at  50%  response 
occurring at 13.3 months. 
MuLV Group IF Antigens.--Frozen sections of lddneys of 8  female NZB 
mice were studied by the indirect immunofluorescence method for the location 
of murine leukemia virus group IF antigens.  Results on two mice were nega- 
tive at 2 months while trace amounts of leukemia viral antigens were detected 
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F~G. 2. Immtmofluorescence  tests for (3 soluble antigen in the plasma of untreated (Q) 
and vaccinated (Zk) NZB mice at various ages. Reactions are graded by proportion of cells 
showing membrane immunofluorescence:  negative (-<20%); positive (>20%). R. C. MELLORS,  T. AOKI,  AND  R.  ~. ]~IJEBNER  1051 
in the glomeruli of one of two mice aged 5 months. Leukemia viral antigens were 
readily identified in the glomeruli  of the remaining  4 NZB mice,  aged 10-15 
months,  with  2-3-[-  proteinuria  and  histologically  confirmed  membranous 
glomerulonephritis.  Leukemia viral antigens were present in the structurally 
altered glomeruli  and mainly deposited focally in the mesangium (Fig. 6), con- 
trasting with a more widespread distribution of host immunoglobulins  in the 
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FIG.  3.  Immunofluorescence tests  for  G  antibody  in  the serum  of untreated  (0)  and 
vaccinated (A) NZB mice at various ages. Reactions are graxted by proportion of cells show- 
ing membrane immunofluorescence: negative (_~20%); positive (>20%). 1052  MURINE LEUKEMIA-L~F.  VIRUS AND NZB MICE 
glomeruli, in keeping with earlier work (16).  Negative control reactions in the 
immunofluorescence  procedure  for  the  detection  of  leukemia  viral  antigens 
included the use of nonlmmune serum and immune serum absorbed with MuLV 
group antigens  (Fig.  7)  as well  as the study of frozen sections  of kidneys of 
Swiss mice aged 2-10 months. 
Direct  Antiglobulin  (Coombs) Tests.--Tests  for  erythrocyte-bound  host 
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1~1o. 4.  Direct antiglobulin Coombs (DC) tests, % positive, continuous line, on untreated 
NZB mice at various ages show positive conversion associated with  G soluble antigen  (O) 
production.  Comparable tests  on vaccinated NZB mice, inoculated at 3rd and 5th wk (ar- 
rows), show nonconversion of Coombs tests and nonproduction of G soluble antigen. R.  C.  MELLORS~ T.  AOKI,  AND  R.  J.  HUEBNER  1053 
globulins  (shown to be immunoglobulins) were performed on  145  untreated 
NZB mice at various ages. The response-time curve (Fig. 4) revealed negative 
reactions at 2 and 3 months followed thereafter by positive conversion; 50 % of 
direct antiglobulin tests were positive at 5.3 months (Table IV) and 99 % were 
positive at 8 months, remaining so thereafter with rare  exception.  As shown 
in Fig. 4, the time-response curve for positive conversion of direct antiglobulin 
tests corresponded closely to that for G soluble antigen production in untreated 
NZB mice. 
As described elsewhere (4, 5), positive conversion of direct antiglobulin tests 
was significantly delayed by vaccinating NZB mice at 3 and 5 wk of age with 
TABLE IV 
50°~o Response  Time (T5o%) for Positive Direct Coombs (DC+ )  Test Conversion and G Antibody 
Production  in  Untreated  and  Vaccinated  NZB  Mice 
Response 
DC-b 
DC-b 
O antibody 
G antibody 
NZB Mice 
Treatment 
Untreated 
Vaccinated 
Untreated 
Vaccinated 
T~0%* 
months 
5.3 
8.7 
13.3 
7.3 
months 
0.2 
0.4 
0.8 
1.4 
SD 
months 
0.9 
1.1 
1.4 
2.6 
N' 
145 
48 
21 
30 
* See footnote, Table III. 
intraperitoneal injections of 0.2 ml formaldehyde-inactivated cell-free filtrate 
of aged NZB mouse spleen.  The 50 % response time for positive  antiglobulin 
test conversion was 8.7 months in vaccinated NZB mice (Table IV)  as con- 
trasted with 5.3 months in untreated NZB mice. Reciprocally, as brought out in 
Table IV and Fig. 3, the 50%  response time for G  antibody production oc- 
curred earlier in vaccinated NZB mice, that is, at 7.3 months as contrasted with 
13.3 months in untreated NZB mice. 
The plasmas of 30 vaccinated NZB mice with negative direct antiglobulin 
reactions at 4, 5, and 7 months of age were tested at the same time for G soluble 
antigen.  The  tests  for G  soluble  antigen were  likewise negative in each in- 
stance (Figs. 2 and 4), that is, nonconversion in antiglobulin tests was corre- 
lated with nonproduction of G soluble antigen in vaccinated NZB mice. 
The erythrocytes of normal untreated Swiss mice always served as negative 
controls in direct antiglobulin tests and gave negative reactions, without ex- 
ception, in all such tests performed throughout the course of this study. 
Proteinuria.--Significant proteinuria as shown by positive reactions greater 
than 1 plus (25) was a functional manifestation of severe diffuse membranous 
glomerulonephritis, in turn the major cause of death of NZB mice, especially 1054  MURINE  LEUKEMIA-LIKE  VIRUS  AND  NZB  MICE 
females, starting at about 10 months of age (26, 18). Proteinuria tests performed 
on 568 female NZB mice at various ages indicated that the response-time curve 
for  significant  proteinuria  (Fig.  5)  was  sigmoid in  shape  and  approximately 
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FIG. 5. Tests  (% positive) for significant proteinuria (A) and tabulation  of cumulative 
mortality  ((D), per  cent, for  untreated  female NZB mice at various ages. Curves for  G 
soluble antigen and G antibody formation (broken line) correspond to Fig. 1. 
linear in  the  age  range  of 9-13 months.  At  12.3  months  (Table V),  50 %  of 
untreated  female NZB mice had significant proteinuria. 
Cumulative  Mortality.--Mortality  statistics  tabulated  on  107  untreated  fe- 
male NZB mice at monthly intervals from weaning to death indicated a  50 % 
response (median  survival) time of 13.3  months (Table V).  The median  sur- 
vival time for 79 untreated male NZB mice was 15.7 months (Table V). R. C. MELLORS, T. AOKI,  AND  R. J. HIIEBNER  1055 
When plotted as a function of age, the points for cumulative mortality of 
untreated female NZB mice fell close to the curve for G antibody production 
(Fig. 5) as did also the 50 % response times,  13.3 months, for cumulative mor- 
tality (Table V) and G antibody production (Table III). 
DISCUSSION 
These  observations  indicate that  MuLV group  antigens are  prevalent in 
spleen, kidneys and, to a lesser extent, thymus of NZB mice throughout a sub- 
stantial portion of their life span. The findings are consistent with the electron 
microscopic demonstration (I, 2, 27-30) of C type, and incomplete,  virus-like 
particles  in the corresponding tissues obtained from late embryo stage to aged 
adult and are in accord  with the pattern of vertical transmission of murine 
TABLE V 
50% Response Time (  Ts~) for Significant Proteinuria (Positive Reaction Greater than 1 +) and 
Cumulative Mortality in Untreated NZB Mice 
Response  Tso%*  -I-2 SE  SD  N ~ 
Significant proteinuria ( 9 ) 
Cumulative mortality 
9 
C 
months 
12.3 
13.3 
15.7 
months 
0.5 
0.3 
0.6 
months 
4.0 
2.0 
3.1 
468 
583 
245 
* See footnote, Table III. 
leukemia virus from one generation to another (31). Further, the present studies 
indicate that NZB mice differ from mice of other G  (Gross) positive inbred 
strains, such as the AKR, in the following respects. G (Gross) soluble antigen is 
not detectable in the plasma of NZB mice until 2-3 months of age and, reaching 
100%  prevalence,  undergoes  elimination thereafter; whereas  this  antigen is 
found in the plasma of other G-positive strains throughout their life span (12- 
14). Moreover,  NZB mice produce  G  (Gross) natural antibody whereas,  ap- 
parently owing to immunological tolerance,  G antibody has not been found in 
other G-positive mouse strains (13, 24). The seeming failure of NZB mice to 
develop lasting tolerance to G antigen may be related to a deficiency in the 
production of this antigen in the early stages of postnatal life or to the more 
general inability of this strain to develop or maintain tolerance  to some other 
antigens  (32). The  paradoxical  effect  of  a  vaccine,  prepared  from formal- 
dehyde-inactivated virus-containing  filtrates  of  older  NZB  mouse  spleens 
(4, 5, 19), in delaying G soluble antigen production and yet raising G antibody 
formation may find explanation in an early antigenic priming effect. 
Murine leukemia virus infection appears  to be widespread and yet, with the 
exception of mouse strains with a high incidence of leukemia, rarely causes ap- 1056  MURINE  LEUKEMIA-LIKE  VIRUS  AND  NZB  MICE 
parent disease until very late in the lifetime of the infected animal (9). Neverthe- 
less by midlife virtually all mice of the NZB strain have autoimmune hemolytic 
disease with positive Coombs tests (33, 34,  26,  18),  the majority have renal 
glomerular disease (membranous glomerulonephritis)  (35, 26, 36, 18), and some 
develop malignant  lymphoma (26,  17, 37, 3, 4) or sarcoma of bone and soft 
tissue (19). 
The present study makes it clear that positive conversion of Coombs tests in 
untreated NZB mice corresponds closely in time to the production of G soluble 
antigen  and that  nonconversion of Coombs tests in vaccinated NZB mice is 
correlated with the nonproduction of G soluble antigen and the earlier produc- 
tion  of  G  antibody. Elsewhere it has  been shown that  accelerated  Coombs 
conversion  (4,  5,  19)  can  be induced  by injecting  weanling  NZB mice with 
passage lines of solid tumors (sarcomas)  indigenous  to the strain and containing 
C type particles and MuLV group antigens. These collective  findings  suggest 
that there is a direct relation between leukemia-like  virus infection and auto- 
immune hemolytic disease of NZB mice. An explanation for such a relation may 
be found in the following considerations.  The surfaces of erythroid and other 
cells may be altered antigenically by budding of virus particles (1, 2, 27-30), 
by presence of G antigen or by some other expression of leukemia virus genome. 
Cell surfaces thus modified  antigenically may raise antibody to the virus-spec- 
ified determinant  and, similar yet not identical  with self, may also abrogate 
self-tolerance,  as suggested by some other experimental systems (38). Alterna- 
tively, cell surfaces may be changed antigenically by adsorption of G soluble 
antigen,  as occurs with EIA indicator cells in the method for detecting this 
antigen  (12).  Nevertheless,  the  fact  that  antibodies  eluted  from  Coombs- 
positive erythrocytes of NZB mice  show specificity for normal,  presumably 
unmodified,  mouse erythrocytes irrespective of strain  (39)  appears  to  argue 
against this latter interpretation, as does also the persistence of positive Coombs 
tests in older NZB mice at the time of elimination  of G soluble antigen. Another 
possibility is that  leukemia-like  virus infection alters the biological  behavior 
and function of lymphoid  cells.  The  prevalence of malignant  lymphoma in 
aged NZB mice (4, 17, 26, 37), the early induction of thymic lymphosarcoma in 
the majority of NZB mice appropriately treated with the immunosuppressive 
drug  azathioprine  (40,  R.  C.  Mellors,  unpublished  observations),  and  the 
identification of C type virus-like particles (1, 2, 4) and MuLV group antigens 
in each lymphoma studied, whether early or late primary or passage line, attest 
to the association of leukemia-like  virus with abnormal lymphoid cells. Con- 
ceivably, autoimmune proliferation of lymphoid cells may be induced by virus 
infection  and  may be a  step in  the direction  of lymphoid neoplasia;  histo- 
pathologically,  autoimmune  and  lymphomatous  proliferations  of  lymphoid 
cells in NZB mice are often di/ficult  to distinguish  from each other (17). 
Renal glomerular disease (membranous glomerulonephritis)  of NZB mice is R. C. MELLORS, T. AOKI, AND R. J. IiuJ~BNER  1057 
almost  certainly immunologically induced and is the main cause d  death~ 
especially of females starting at about 10 months of age (35, 26, 36, 16, 18). 
The present studies indicate that proteinuria, a functional manifestation of the 
glomerular lesions,  becomes increasingly prevalent as  G  soluble  antigen is 
eliminated from the plasma of female NZB mice and that cumulative mortality 
occurs in phase with free G  antibody production. Further, MuLV group IF 
antigens and host immunoglobulins  are localized in the glomerular lesions of 
NZB mice with renal disease. These collective findings suggest that leukemia- 
like virus is implicated in the etiology of glomerulonephritis of NZB mice. It is 
also reasonable to suggest that, with waning of tolerance and mounting of an 
immune response to G antigen, G antibody is formed and in turn circulating 
G soluble antigen-antibody complexes; the latter, if deposited in the glomeruli, 
may contribute to the development of glomerulonephritis.  As noted by electron 
microscopic  study (1), routine leukemia virus-like particles are present occa- 
sionally in the urinary space and the tubular lumens of the glomeruli of NZB 
mice and frequently in the basal infoldings  of the renal convoluted tubules. 
The present study is the first to implicate a  virus-specified  cell-surface  and 
soluble  antigen in the immunopathogenesis of renal glomerular disease.  The 
several immunological  mechanisms for the induction of experimental glomerulo- 
nephritis in other systems are discussed elsewhere (41, 42). Recent findings in 
lymphocytic choriomeningitis (LCM) of neonatally infected mice indicate that 
the deposition  of LCM  virus,  antibody, and  complement in  the glomeruli 
(43) may be one of the causes of the glomerulonephritis  which occurs late in the 
course of this infection (44). 
Approximately 5 % of adult NZB mice have positive lupus erythematosus 
(LE) cell tests (34, 35) and a larger proportion develop anti-nuclear antibodies 
(45). NZB/W Ft hybrid mice have a high incidence of positive LE cell tests 
accompanied by an early onset of fatal renal disease (35). DNA and anti-DNA 
antibodies, presumably deposited as nuclear antigen-antibody complexes, are 
implicated in the pathogenesis of glomerulonephritis in NZB/W hybrid mice 
(46). While the relation of anti-nuclear antibody formation to leukemia-like 
virus infection is presently unknown, although under investigation, it would be 
surprising not to find some common factors in the etiology and the pathogenesis 
of renal glomerular disease of NZB inbred and hybrid mice. This seems all the 
more likely in as much as hemolytic, renal, and lymphomatous disorders similar 
to those arising in NZB mice were induced in 10-20 % of Swiss mice by neonatal 
inoculation of cell-free filtrates of freshly prepared homogenates of transplant- 
able lymphomas and enlarged spleens of 10 to 20 month old NZB mice (2-5). 
Nevertheless, the leukemia-like virus of NZB mice has not yet been isolated in 
tissue culture despite rather extensive efforts with newer techniques such as 
those used successfully in related systems (7, 8, 47). 
A remaining consideration is that of contaminating viruses. While the colony 1058  M~RINE  LEIYKEM~IA-LIKE  VIRUS  AND  NZB  MICE 
of NZB mice used in this study is free of reovirus 3, lymphocytic choriomenin- 
gitis, and several other defined murine viruses, there is serological evidence of 
contamination of the colony with polyoma and GD  VII virus,  as previously 
reported (2, 4). It may be necessary to exclude polyoma virus as a factor in the 
accelerated  Coombs conversion  (4, 5, 19) induced in NZB mice with passage 
lines of isologous sarcomas, should these tumors carry polyoma. 
SI.r~MARY 
Further evidence implicating murine leukemia-like virus in the disorders  of 
NZB mice was afforded by a study of antigens associated with murine leukemia 
virus  (MuLV). MuLV group antigens were prevalent in extracts of spleen, 
kidney, and, to a lesser extent, thymus throughout a substantial portion of the 
life span of NZB mice as well as in extracts of lymphomas and sarcomas  in- 
digenous to the strain. 
G (Gross) soluble antigen, type-specific antigen, was first detected in plasma 
of untreated NZB mice at 3 months of age. G soluble antigen production in- 
creased thereafter in line with age, with 50 % of reactions becoming positive at 
5.3 months and 100 % at 7 to 9 months. 
From months 3 to 9, the time-response curve for positive conversion of direct 
antiglobulin (Coombs)  tests in untreated NZB mice corresponded  closely to 
that for G soluble antigen production. 
Beyond the 9th month, G soluble antigen underwent elimination from the 
plasma of NZB mice, with positive reactions reduced to 50 % at 13.3 months and 
to 0 % at 18 months. G natural antibody was first detected in the serum of NZB 
mice at about 10 months of age and increased thereafter in line with age. The 
curves for G antibody production and G soluble antigen elimination bore a re- 
ciprocal relation to each other with crossover at 50 % response occurring at 13.3 
months. 
Significant proteinuria, a functional manifestation of membranous glomeru- 
lonephritis,  became increasingly  prevalent in female  NZB mice as G soluble 
antigen was  eliminated from plasma.  Cumulative mortality of female NZB 
mice, mainly attributable to renal glomerular disease, increased in phase with 
G antibody production. MuLV group antigens were identified in the glomerular 
lesions by the immunofluorescence method. 
Positive conversion of direct antiglobulin  tests was significantly delayed by 
vaccinating baby NZB mice with formaldehyde-inactivated  cell-free filtrates of 
older NZB mouse spleens. The plasmas of vaccinated NZB mice with negative 
direct antiglobulin reactions  at 4  to 7 months were likewise negative when 
tested for G soluble antigen. The 50 % response time for G antibody production 
in the vaccinated NZB mice occurred at 7.3 months, that is, 6 months earlier 
than in untreated NZB mice. 
The collective findings implicate murine leukemia-like virus in the etiology of R.  C.  MELLORS~ T.  AOKI~ AND  R.  J.  HUEBNER  1059 
autoimmune hemolytic disease and membranous glomerulonephritis, as well as 
malignant lymphoma, of NZB mice and suggest that virus-specified cell-surface 
and soluble antigen is a  factor in the immunopathogenesis of the renal disease 
and  possibly  also  the  autoimmune  hemolytic  disease. 
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FIG.  6.  Immunofluorescence photomicrographs of frozen sections of kidney of  13 
month old NZB  mouse with  3+  proteinuria and membranous glomerulonephritis. 
Murine leukemia viral antigens  (white  areas)  located  eccentrically in glomerulus 
(left and right), mainly in mesangium. Indirect procedure using MuLV group rat 
antiserum followed  by fluorescent anti-rat globulin, neither of which reagents react 
with mouse serum proteins (see Methods and Materials). ×  400. 
FIG.  7.  Negative  control reactions  for  Fig.  6.  Frozen  sections of  same  kidney 
reacted with MuLV group rat antiserum absorbed with MuLV group antigens (left) 
and reacted with homologous normal rat serum (right), followed  in each instance by 
fluorescent anti-rat globulin. Glomeruli are barely visible; there is no specific immuno- 
fluorescence.  ×  400. 